logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Takeda To Acquire Nimbus Therapeutics’ Highly Selective, Allosteric Tyk2 Inhibitor To Address Multiple Immune-Mediated Diseases

Dec 13, 2022•about 3 years ago

Acquiring Company

Maverick Therapeutics

Acquired Company

Nimbus Therapeutics

TokyopharmaceuticalsTherapeuticsPharmaceuticalBiotechnologyHealth Care

Description

Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced that it has signed a definitive agreement under which Takeda (TSE:4502/NYSE:TAK) will acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858 is an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.

Company Information

Company

Maverick Therapeutics

Location

Tokyo, Tokyo, Japan

About

Maverick Therapeutics is a biotechnology company specializing in the development of T cell therapy for solid tumors. It aims to enhance the efficacy and safety of T cell therapies through its proprietary COBRA platform. The company was recognized as a leader in T cell therapy technologies.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed